secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066915
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Q1 revenue $52.6M (+3% YoY); net loss improves to $(15.9)M; reaffirms FY2025 guidance
--------------------------------------------------------------------------------

- Revenue $52.6M, up 3% from $51.1M; adjusted for one less selling day, growth 4.5%.
- Net loss $(15.9)M ($(0.25)/share) vs $(18.7)M ($(0.30)/share) in Q1 2024, improved 15%.
- Adjusted EBITDA $(3.8)M, a 53% improvement from $(8.3)M in prior-year quarter.
- Reaffirms FY2025 revenue guidance $224-230M (7-10% growth) and breakeven adjusted EBITDA.
- Launched three new bunion systems (Nanoplasty, Percuplasty 3D MIS, SpeedMTP MTP Fusion).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017025066915/0000950170-25-066915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017025066915/tmci-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer